- Previous Close
1.140 - Open
1.130 - Bid 1.230 x --
- Ask 1.250 x --
- Day's Range
1.130 - 1.250 - 52 Week Range
0.800 - 1.990 - Volume
5,005,000 - Avg. Volume
1,403,486 - Market Cap (intraday)
894.504M - Beta (5Y Monthly) 1.50
- PE Ratio (TTM)
-- - EPS (TTM)
-0.380 - Earnings Date Mar 20, 2025 - Mar 24, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
0.97
Brii Biosciences Limited engages in the research and development of therapies for the treatment of infectious and central nervous system diseases in China and the United States. The company develops BRII-179, BRII-835, and BRII-877, which are in Phase 2 the development of a functional cure for HBV for Hepatitis B; BRII-179, a recombinant protein-based HBV immunotherapeutic candidate that is in Phase 2; and BRII-732 that is in Phase 1 clinical trial and BRII-753, which is in preclinical stage for the treatment of HIV. It develops BRII-296 for the treatment of PPD/MDD, anxiety, and other depressive disorders; BRII-297 for treatment of various depressive disorders; BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative infections; and BRII-658 for oral treatment for patients with chronic NTM lung disease. Brii Biosciences Limited was incorporated in 2017 and is headquartered in Beijing, China.
www.briibio.comRecent News: 2137.HK
View MorePerformance Overview: 2137.HK
Trailing total returns as of 1/16/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 2137.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 2137.HK
View MoreValuation Measures
Market Cap
829.05M
Enterprise Value
-1.68B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.27
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-10.12%
Return on Equity (ttm)
-9.18%
Revenue (ttm)
38.38M
Net Income Avi to Common (ttm)
-265.45M
Diluted EPS (ttm)
-0.380
Balance Sheet and Cash Flow
Total Cash (mrq)
2.39B
Total Debt/Equity (mrq)
0.07%
Levered Free Cash Flow (ttm)
-412.1M